

AMENDMENTS TO THE SPECIFICATION

Please insert the following as the first paragraph beneath the title on page one of the specification:

This application is the National Stage of International Application No. PCT/EP04/001692, filed on February 20, 2004, which claims benefit under 35 U.S.C. §119(e) of U. S. Provisional Application No. 60/449,018, filed on February 21, 2003, the contents of both are incorporated herein by reference in their entirety.

On page 5 of the application, kindly replace the second and third paragraphs with the following paragraphs:

In another embodiment this invention provides a method of predicting the likelihood of a Type 1 event occurring during treatment of a patient, who is or may be at risk for the occurrence of a Type 1 event, comprising, making the genotype determination as described above, wherein, (a) if said patient is classed as AA then they will be considered to be in risk Category I, and (b) if said patient is classed as GA then they will be considered to be in risk Category II, and, (c) if said patient is classed as GG then they will be considered to be in risk Category III.

In still another embodiment this invention provides methods for making the above determinations utilizing a surrogate marker for the SLC6A3 Exon 9 A59G polymorphism. This method involves predicting the likelihood of a Type 1 event occurring during treatment of a patient, who is or may be at risk for the occurrence of a Type 1 event, comprising, making the determination whether or not a surrogate marker for the SLC6A3 Exon 9 A59G polymorphism is present in the said patient, wherein, (a) if said surrogate marker indicates that said patient should be classed as AA then they will be considered to be in risk Category I, and (b) if said surrogate marker indicates that said patient should be classed as GA then they will be considered to be in risk Category II, and (c) if said surrogate marker indicates that said patient should be classed as GG then they will be considered to be in risk Category III.

On page 14 of the application, kindly replace the first paragraph part with the following paragraph part:

assessment. A patient in a Category II risk group would be expected to be at a relatively greater risk of a Type 1 event during a given period of time. The increased risk may be 1.5, 2.0, 3.0 or 4.0 times the risk of a patient in Category I. A patient in Category III would be at the highest risk for a Type 1 event and this increased risk would be 3.0, 4.0, 5.0 or more times the risk as compared to a patient in Category I. This increased risk would be reflected in a greater likelihood of the patient engaging in suicidal or self destructive behavior or experiencing a Type 1 event during a given period of time.

On page 35 of the application, kindly replace the last paragraph part with the following paragraph part:

The invention also provides a method for determining the frequency of a SLC6A3 genotype or SLC6A3 haplotype in a population. The method comprises determining the genotype or the haplotype pair for the SLC6A3 gene that is present in each member of the population, wherein the genotype or haplotype comprises the nucleotide pair or nucleotide detected at one or more of the polymorphic sites in the SLC6A3 gene including, but not limited to, the A59G polymorphism; and calculating the frequency any particular genotype or haplotype is found in the population. The population may be a reference

The Abstract is submitted herewith on a separate sheet and should be inserted in the specification following the Claims.